GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
Operating Expenses
GlaxoSmithKline Pharmaceuticals Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
|
Operating Expenses
-₹12.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Expenses
-₹152.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Expenses
-₹123.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Expenses
-₹288.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Expenses
-₹57.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Operating Expenses
-₹47.9B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline Pharmaceuticals Ltd
Glance View
GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.
See Also
What is GlaxoSmithKline Pharmaceuticals Ltd's Operating Expenses?
Operating Expenses
-12.7B
INR
Based on the financial report for Dec 31, 2024, GlaxoSmithKline Pharmaceuticals Ltd's Operating Expenses amounts to -12.7B INR.
What is GlaxoSmithKline Pharmaceuticals Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
0%
Over the last year, the Operating Expenses growth was -2%. The average annual Operating Expenses growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been -4% over the past three years .
You don't have any saved screeners yet